Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Apellis Pharmaceuticals,Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will participate in the following upcoming investor conferences in September:


GlobeNewswire Inc | Sep 2, 2020 07:00AM EDT

September 02, 2020

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will participate in the following upcoming investor conferences in September:

-- Baird 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 2:35 p.m. ET -- Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020 at 9:50 a.m ET and 3:20 p.m. ET -- Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 2:40 p.m. ET

Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat at the Baird 2020 Global Healthcare Conference, an ophthalmology panel discussion titled Seeing 20/20 in 2020 at the Citi 15th Annual BioPharma Virtual Conference, a fireside chat at the Citi 15th Annual BioPharma Virtual Conference, and a fireside chat at the Cantor Virtual Global Healthcare Conference.

The events will be available via live webcast from the Events and Presentations page of the Investors and Media section of the companys website at https://investors.apellis.com/events-and-presentations. Replays of the webcasts will be available for 90 days following the event.

About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.

Investor Contact: Sam Martin / Maghan Meyers Argot Partners sam@argotpartners.com / maghan@argotpartners.com 212.600.1902







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC